New trials, publications, preprints and grants on this target, month by month.
Trial
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
1 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Assessment of genomic instability and homologous recombination repair in ovarian cancer using the Oncomine Comprehensive Assay Plus.
5 Nov 2026· Oncotarget· PUBMED
Publication
Male breast cancer: clinicopathological features and prevalence of germline pathogenic variants.
4 Nov 2026· Breast cancer research and treatment· PUBMED
Publication
Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study.
3 Nov 2026· JCO precision oncology· PUBMED
Publication
Impact of BRCA2, BRCA1, and Other Individual Homologous Recombination Repair Alterations on Survival in Metastatic Castration-resistant Prostate Cancer.
3 Nov 2026· European urology oncology· PUBMED
Publication
The effect of germline mutations on survival outcomes of breast cancer - Study from a tertiary care center in North India.
29 Oct 2026· Journal of cancer research and therapeutics· PUBMED
Publication
Germline BRCA-Lynch syndrome MINAS: report of six Argentinian families and a systematic review of the literature.
28 Oct 2026· Familial cancer· PUBMED
Publication
Multi-omics analysis of high-grade serous ovarian cancers reveals heterogeneity and distinct immunological patterns based upon clinico-genomic status.
22 Oct 2026· PLoS genetics· PUBMED
Publication
Identification and characterization of shared transcriptomic signatures in BRCA2-mutated metastatic breast cancer and lung adenocarcinoma: An integrative bioinformatics approach.
22 Oct 2026· Mutation research· PUBMED
Publication
Correlation between BRCA mutational status and lymph node metastasis in advanced epithelial ovarian cancer: a retrospective study.
20 Oct 2026· PeerJ· PUBMED
Publication
Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study.
15 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Cancer risks associated with BRCA1 and BRCA2: Overview and management.
15 Oct 2026· Cancer· PUBMED
Publication
Large-scale integration of functional assay data for the resolution of germline BRCA1 and BRCA2 variants of uncertain significance.
12 Oct 2026· American journal of human genetics· PUBMED
Publication
Case Report: Coexpression of somatic EGFR, BRCA1, and BRCA2 mutations in metastatic non-small cell lung cancer.
8 Oct 2026· Frontiers in oncology· PUBMED
Publication
Olaparib plus tremelimumab in women with recurrent ovarian cancer and a germline BRCA1 or BRCA2 mutation: a phase I/II study.
8 Oct 2026· Nature communications· PUBMED
Publication
Re: Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Five-year Results of the IMPACT Study.
6 Oct 2026· European urology· PUBMED
Trial
Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants
1 Oct 2026· NA · NOT_YET_RECRUITING· CTGOV
Publication
Radiogenomic Analysis of Contrast-Enhanced MRI for Predicting Pathogenic BRCA Variants in Ovarian Cancer.
1 Oct 2026· Acta medica Okayama· PUBMED
Publication
Survival After Risk-Reducing Mastectomy in Patients With Pathogenic Variants in BRCA1 and BRCA2: A Network Meta-Analysis.
1 Oct 2026· JAMA network open· PUBMED
Publication
Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions.
1 Oct 2026· The Journal of clinical investigation· PUBMED
Publication
Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer.
1 Oct 2026· Cancer research communications· PUBMED
Publication
Unified genetic risk score for prostate cancer enables improved risk stratification for clinical decision-making.
29 Sept 2026· Journal of medical genetics· PUBMED
Publication
Clinical implications of the type and genomic location of pathogenic BRCA1 and BRCA2 variants in hereditary breast and ovarian cancer.
29 Sept 2026· Critical reviews in oncology/hematology· PUBMED
Publication
Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer.
29 Sept 2026· European journal of cancer (Oxford, England : 1990)· PUBMED
Publication
Risk-reducing salpingo-oophorectomy in patients with gBRCA-mutated breast cancer.
28 Sept 2026· Archives of gynecology and obstetrics· PUBMED
Publication
Clinical impact of ENIGMA-based variant reclassification on genotype-phenotype analyses in BRCA1- and BRCA2-associated hereditary breast and ovarian cancer.
25 Sept 2026· Breast cancer (Tokyo, Japan)· PUBMED
Publication
Pathogenic germline variants in BRCA1/2 are associated with a decreased number of hypomethylated rDNA copies.
25 Sept 2026· Breast cancer research : BCR· PUBMED
Publication
Bridging the BRCA1/2 variant previvor gap in health care.
24 Sept 2026· JAAPA : official journal of the American Academy of Physician Assistants· PUBMED
Publication
Pancreatic Intraductal Papillary Mucinous Neoplasm in a Carrier of a Reported Pathogenic BRCA2 Variant: Diagnostic Considerations and Management Using European and International Guidelines.
24 Sept 2026· Cureus· PUBMED
Publication
Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.
23 Sept 2026· Signal transduction and targeted therapy· PUBMED